Semaglutide formulation and pen comparison study aims for bioequivalence in healthy volunteers

Semaglutide, a GLP-1 receptor agonist, is a cornerstone in managing Type 2 Diabetes Mellitus and obesity. Its efficacy relies on consistent systemic exposure. Pharmaceutical companies continually refine drug formulations and delivery devices to improve patient experience, manufacturing efficiency, or stability. Ensuring that new formulations or pen-injectors deliver the same drug levels as existing ones is critical for maintaining therapeutic equivalence and patient safety. This study addresses the need to confirm bioequivalence for a new semaglutide version and its associated pen-injector.

This is a bioequivalence study protocol comparing two different once-weekly semaglutide versions delivered via distinct pen-injectors. Participants will be randomly assigned to receive one of the two semaglutide versions. Each participant will receive 7 once-weekly injections of their assigned semaglutide version, administered subcutaneously (SC) in the abdomen using a pen-injector. The total study duration is approximately 80-106 days, involving 19 study visits. Two visits require an inpatient stay: one for 2 days and 1 night, and another for 4 days and 3 nights, likely for intensive pharmacokinetic sampling. The primary endpoint is to demonstrate similar blood levels of semaglutide between the two versions.

This record describes a study protocol, and as such, specific results are not yet available. The primary objective is to demonstrate bioequivalence between the two semaglutide versions. Researchers will measure pharmacokinetic parameters such as maximum concentration (Cmax) and area under the curve (AUC) to assess how the different formulations and pens affect drug absorption and exposure. The study aims to confirm that the new semaglutide version and its pen deliver comparable systemic levels of the drug to the already prescribed version, ensuring consistent therapeutic effects. Secondary outcomes will likely include safety and tolerability profiles, although detailed adverse event reporting is not the primary focus of this bioequivalence study. The study will determine if the new formulation maintains the established GLP-1R agonism profile.